1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

LAMEA Oncology/Anti-cancer drugs Market - Opportunities and Forecasts, 2014 - 2021

  • February 2016
  • Allied Market Research
Report ID: 3704404

Summary

Table of Contents

Oncology/Anti-cancer drugs are used for treating various cancer types for improving and prolonging a patients survival time. Biological drugs, based on monoclonal antibodies (mAbs) would emerge as a preferred option for treating various cancer types, especially blood cancer (leukaemia). The rising incidence and prevalence of various cancer types, new cancer treatments and growing importance of biological and targeted drug therapies, are driving the market growth of LAMEA oncology/anti-cancer drugs. In addition, increasing demand of anti-cancer drugs for the treatment of ageing population, rising government funds and improved treatment results, are major factors boosting the market growth. However, the high cost involved in new drug development, coupled with threat of failure and adverse effects associated with anti-cancer drugs therapies, would restrain the growth of the LAMEA market. Moreover, accessibility of anti-cancer drugs incurred by high cost, is a major challenge that is expected to further impede the performance of anti-cancer drugs in LAMEA region. Nevertheless, commercialization of advanced therapeutics, such as targeted therapies and immunotherapies (biologic therapies) would reduce the negative influence of restraints and fuel the market growth.The LAMEA oncology drugs market is segmented into therapeutic modalities, cancer types and countries. Therapeutic modalities segment is further categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy and others. The LAMEA oncology drugs market is expected to reach $17,072.2 million by 2021. Patent expiration of key anti-cancer drugs such as Herceptin (Patent Expiration: EU-2014; US-2019), Erbitux (Patent Expiration: EU-2014; US-2016), Rituxan (Patent Expiration: EU-2013; US-2018) and Avastin (Patent Expiration: EU-2018; US-2019), is expected to boost the growth of cancer biosimilars market by 2021. Further, the biological therapy is the fastest growing segment at a CAGR of 12.2%, throughout the analysis period, on account of high efficacy and target specific action. Moreover, blood cancer drugs market was the largest revenue generating application segment in 2015, owing to the high cost of drugs (immunotherapies), used for the treatment of blood cancer.Based on countries the LAMEA region is segmented into nine countries named Brazil, Argentina, Nigeria, South Africa, Iraq, Iran, Algeria, Saudi Arabia and Egypt. Brazil dominates the LAMEA market closely followed by Argentina, owing to rising incidence of cancer, high expenditure and gross national income (GNI) of Brazil specifically. In addition, LAMEA market is poised to grow at a promising CAGR of 8.6% during the forecast period. This high growth rate is majorly attributed to the increasing awareness towards advanced therapies, namely immunotherapies and increase in per capita healthcare spending.The key companies profiled in the report include Amgen Inc., AstraZeneca Plc., Roche Diagnostics, GlaxoSmithKline PLC, Merck & Co., Novartis AG, AbbVie Inc. Sanofi, EIMC United Pharmaceuticals (EUP) and Actavis plc.

KEY BENEFITS
:The report provides quantitative analysis of the current market and estimations through 2014-2021 that assists in identifying the prevailing market opportunities.The report helps in understanding the strategies adopted by various companies for gaining market share in the anti-cancer drugs market.The report provides a comprehensive analysis of factors that drive and restrict the growth of the LAMEA anti-cancer drugs market.Market conditions of anti-cancer drugs market across LAMEA region are comprehensively analyzed.Competitive intelligence highlights the business practices followed by leading market players across various geographies.SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET KEY SEGMENTS:LAMEA oncology/anti-cancer drugs market is segmented into therapeutic modalities, cancer types and countries.By Therapeutic modalitiesChemotherapyTargeted TherapyImmunotherapy (Biologic Therapy)Hormonal TherapyOthersBy Cancer TypesBlood CancerBreast CancerGastrointestinal CancerRespiratory/Lung CancerSkin CancerOther CancersBy CountriesBrazilArgentinaNigeriaSouth AfricaIraqIranAlgeriaSaudi ArabiaEgyptOther LAMEA countries

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Cancer Diagnostics Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Emerging Tumor Markers, Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 52400
  • Industry report
  • May 2017
  • by Venture Planning Group

This new 74-country report from VPGMarketResearch.com is available by region, country, market segment, section, or individual test. This report is designed to assist diagnostics industry executives, as ...

Europe Cancer Diagnostics Market 2021: A 31-Country Analysis--Supplier Shares and Strategies, Emerging Tumor Markers, Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 36000
  • Industry report
  • May 2017
  • by Venture Planning Group

This new 31-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test. This report is designed to assist diagnostics industry executives, as well as ...

2017 World Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 21100
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. VPGMarketResearch.com's new report is a seven-country strategic analysis of the major business opportunities ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.